Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms

Future Oncol. 2016 Aug;12(16):1877-85. doi: 10.2217/fon-2016-0031. Epub 2016 May 9.

Abstract

Aim: To determine the efficacy of (90)Y [DOTA(0), D-Phe(1), Tyr(3)]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs).

Patients & methods: The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response.

Results: Median PFS in pancreatic and small bowel NETs was 25 and 28 months, respectively, and median OS was 42 and 38.5 months, respectively. No intergroup differences in median OS (p = 0.945) or PFS (p = 0.174) were found, also after adjustment for tumor origin, secretory status and grade, and patient's gender.

Conclusion: (90)Y-DOTATATE may have similar efficacy in pancreatic and small bowel NETs. Better WHO performance status at baseline seems to be associated with more favorable outcomes.

Keywords: 90Y-DOTATATE therapy; GEP-NET; clinical and radiological response.

Publication types

  • Clinical Trial, Phase II

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Disease-Free Survival
  • Female
  • Humans
  • Intestinal Neoplasms / drug therapy*
  • Intestinal Neoplasms / mortality
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neuroendocrine Tumors / drug therapy*
  • Neuroendocrine Tumors / mortality
  • Octreotide / analogs & derivatives*
  • Octreotide / therapeutic use
  • Organometallic Compounds / therapeutic use*
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / mortality
  • Proportional Hazards Models
  • Radiopharmaceuticals / therapeutic use

Substances

  • 90Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)-
  • Antineoplastic Agents
  • Organometallic Compounds
  • Radiopharmaceuticals
  • Octreotide